SYMBICORT® in the Treatment of COPD
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: COPD
Phase: N/A
Status: Completed
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
E Louis, PR, Principal Investigator, Affiliation: Université Libre de Liège
Summary
A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment
of COPD in real life environment by General Practitioners
Clinical Details
Official title: A Scientific Research Program to Evaluate the Efficacy of SYMBICORT® 320/9μg in the Treatment of COPD in Real Life Environment by General Practitioners
Study design: N/A
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients (m/f) with COPD (GOLD stadium III and IV)
Exclusion Criteria:
- patients who recently quit smoking (<3months)
Locations and Contacts
Additional Information
Starting date: March 2006
Ending date: November 2007
Last updated: November 26, 2007
|
